These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results

ANI Pharmaceuticals Inc (NASDAQ: ANIP ) reported upbeat earnings for the second quarter on Friday. The company posted quarterly earnings of $2.21 per share which beat the analyst consensus estimate of $2.05 per share. The company reported quarterly sales of $266.044 million which beat the analyst consensus estimate of $260.128 million. ANI Pharmaceuticals affirmed FY2026 adjusted EPS guidance of $9.19-$9.69 and also affirmed sales forecast of $1.080 billion-$1.140 billion. “In the second quarter, we delivered outstanding financial results, while we implemented the largest Rare Disease sales force expansion in our history,” said Nikhil Lalwani, President and CEO of ANI. “Leading indicators from our gout expansion for Cortrophin Gel are very positive, with the team rapidly delivering a large funnel of new patient cases, with significant breadth and depth of prescribing...